Skip to main navigation
Skip to search
Skip to main content
Tel Aviv University Home
Update Request & User Guide (TAU staff only)
Link opens in a new tab
Search content at Tel Aviv University
Home
Experts
Research units
Research output
Datasets
Prizes
Activities
Press/Media
Topical bevacizumab for neovascular glaucoma: A pilot study
Michael Waisbourd
, Gabi Shemesh
,
Shimon Kurtz
,
Rony Rachmiel
,
Elad Moisseiev
,
Shiri Zayit-Soudri
,
Anat Loewenstein
,
Irina Barequet
Ophthalmology
Tel Aviv University
Research output
:
Contribution to journal
›
Article
›
peer-review
16
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Topical bevacizumab for neovascular glaucoma: A pilot study'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Topical Bevacizumab
100%
Neovascular Glaucoma
100%
Bevacizumab
60%
Day 14
40%
Intraocular Pressure
40%
Iris Neovascularization
40%
Heart Rate
20%
Visual Acuity
20%
Topical Application
20%
Systemic Blood Pressure
20%
Neovascularization
20%
Low Intraocular Pressure
20%
Cornea
20%
Slit Lamp
20%
Ocular Pathology
20%
Mean Reduction
20%
Bullae
20%
Anti-vascular Endothelial Growth Factor (anti-VEGF)
20%
Avastin
20%
Systemic Side Effects
20%
Corneal Epithelial
20%
Ocular Side Effects
20%
Intravitreal Administration
20%
Slit Lamp Examination
20%
Superficial Punctate Keratitis
20%
Upper Eyelid Defect
20%
Nursing and Health Professions
Pilot Study
100%
Bevacizumab
100%
Neovascular Glaucoma
100%
Intraocular Pressure
50%
Neovascularization (Pathology)
50%
Adverse Event
33%
Blood Pressure
16%
Topical Drug Administration
16%
Slit Lamp
16%
Visual Acuity
16%
Vasculotropin
16%
Blister
16%
Intravitreal Drug Administration
16%
Slit Lamp Microscopy
16%
Punctate Keratitis
16%
Medicine and Dentistry
Bevacizumab
100%
Neovascular Glaucoma
100%
Intraocular Pressure
50%
Adverse Event
33%
Iris
33%
Blood Pressure
16%
Vasculotropin
16%
Visual Acuity
16%
Topical Drug Administration
16%
Blister
16%
Intravitreal Administration
16%
Upper Eyelid
16%
Slit Lamp Microscopy
16%
Ocular Pathology
16%
Thygeson Superficial Punctate Keratitis
16%
Pharmacology, Toxicology and Pharmaceutical Science
Bevacizumab
100%
Neovascular Glaucoma
100%
Neovascularization (Pathology)
50%
Adverse Event
33%
Vasculotropin
16%
Blister
16%
Intravitreal Administration
16%
Punctate Keratitis
16%